Vaccinia virus mutants useful for cancer immunotherapy Grant US-11884939-B2 United States of America 30 Jan 2024
USE OF INACTIVATED NONREPLICATING MODIFIED VACCINIA VIRUS ANKARA (MVA)AS… Application EP-4122492-A1 European Patent Office 25 Jan 2023
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with… Grant US-11541087-B2 United States of America 03 Jan 2023
FLT3 ligand fusion proteins and methods of use Grant US-11542308-B2 United States of America 03 Jan 2023
Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as… Grant US-11426460-B2 United States of America 30 Aug 2022
Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic… Grant US-11285209-B2 United States of America 29 Mar 2022
Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors Grant US-11253560-B2 United States of America 22 Feb 2022
Vaccinia virus mutants useful for cancer immunotherapy Grant US-11242509-B2 United States of America 08 Feb 2022
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with… Grant US-10765711-B2 United States of America 08 Sep 2020
Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic… Grant US-10736962-B2 United States of America 11 Aug 2020
Quantitative in situ characterization of biological samples Application US-9778263-B2 United States of America 03 Oct 2017
USE OF INACTIVATED NONREPLICATING MODIFIED VACCINIA VIRUS ANKARA (MVA)AS… Application WO-2016144564-A2 World Intellectual Property Organisation (WIPO) 15 Sep 2016